Company Profile
Genelux Stock Price, News & Catalysts
- Ticker:
- GNLX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.70 USD (-1.46%)
Close
Last updated: August 17, 2026
132M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, GNLX closed down 1.46% at $2.70. No new same-company headline was identified in the current news window.
Company overview
Oncolytic Immunotherapy
Genelux develops replication-competent oncolytic viruses designed to destroy tumor cells and stimulate systemic antitumor immunity. Its platform is being studied through regional and systemic administration approaches.
Olvi-Vec
Olvi-Vec is the company's lead vaccinia-virus candidate. The registrational OnPrime/GOG-3076 study evaluates intraperitoneal Olvi-Vec followed by chemotherapy and bevacizumab in platinum-resistant or refractory ovarian cancer.
Systemic Lung-Cancer Programs
Genelux is also advancing systemic Olvi-Vec studies in lung cancer, seeking to extend the platform beyond tumors accessible through localized administration.
Future catalysts
- Topline data from the Phase 3 OnPrime/GOG-3076 study of Olvi-Vec in ovarian cancer in the second half of 2026.
- Dose-escalation updates from systemic Olvi-Vec studies in lung cancer during 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Genelux (GNLX)?
Genelux (GNLX) most recently closed at 2.70 USD, a -1.46% move versus the previous session.
What is the market cap of Genelux (GNLX)?
Genelux currently has a market capitalization of 132M USD on BioPharmSignal.
What does Genelux do?
Oncolytic Immunotherapy Genelux develops replication-competent oncolytic viruses designed to destroy tumor cells and stimulate systemic antitumor immunity. Its platform is being studied through regional and systemic administration approaches. Olvi-Vec Olvi-Vec is the company's lead vaccinia-virus candidate. The registrational OnPrime/GOG-3076 study...
On which exchange is GNLX stock listed?
Genelux (GNLX) is associated with NASDAQ, United States, Biopharma.
What is GOG-3076?
Topline data from the Phase 3 OnPrime/GOG-3076 study of Olvi-Vec in ovarian cancer in the second half of 2026.
Which conditions is Genelux targeting with GOG-3076?
Genelux is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Genelux describe recent progress with GOG-3076?
Topline data from the Phase 3 OnPrime/GOG-3076 study of Olvi-Vec in ovarian cancer in the second half of 2026.
What is bevacizumab?
The registrational OnPrime/GOG-3076 study evaluates intraperitoneal Olvi-Vec followed by chemotherapy and bevacizumab in platinum-resistant or refractory ovarian cancer.